

# William G Powderly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1345002/publications.pdf>

Version: 2024-02-01

238  
papers

20,102  
citations

18887

64  
h-index

12638

137  
g-index

244  
all docs

244  
docs citations

244  
times ranked

14212  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 1408-1418.	2.9	12
2	SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. <i>Annals of Epidemiology</i> , 2022, 71, 31-37.	0.9	8
3	Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 75, 2060-2065.	2.9	24
4	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010547.	2.1	12
5	Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort. <i>Clinical Infectious Diseases</i> , 2021, 73, e3727-e3732.	2.9	20
6	Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease. <i>Mycoses</i> , 2021, 64, 174-180.	1.8	4
7	A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status. <i>Medical Mycology</i> , 2021, 59, 624-633.	0.3	14
8	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e96.	0.3	11
9	Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1360-1370.	0.9	2
10	Long-Term Mortality after Histoplasma Infection in People with HIV. <i>Journal of Fungi (Basel)</i> , 2021, 6, 1053-1067.	1.5	5
11	Clinical predictive models of invasive <i>Candida</i> infection: A systematic literature review. <i>Medical Mycology</i> , 2021, 59, 1053-1067.	0.3	2
12	Outcomes Associated With Social Distancing Policies in St Louis, Missouri, During the Early Phase of the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2123374.	2.8	6
13	COVID-19 and Outpatient Parenteral Antimicrobial Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 142.	2.0	0
14	Understanding Drivers of Coronavirus Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing Among Black and White Populations. <i>Clinical Infectious Diseases</i> , 2021, 73, e2921-e2931.	2.9	33
15	A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative People in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 252-261.	2.9	68
16	Risk factors predicting <i>Candida</i> infective endocarditis in patients with candidemia. <i>Medical Mycology</i> , 2020, 58, 593-599.	0.3	18
17	Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: A cohort study. <i>EClinicalMedicine</i> , 2020, 27, 100563.	3.2	11
18	Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSA. <i>Journal of Infectious Diseases</i> , 2020, 222, S554-S559.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. <i>Science Advances</i> , 2020, 6, .	4.7	204
20	Adopting locally the lessons learned globally: a call to action for academic medical centres in the USA. <i>BMJ Global Health</i> , 2020, 5, e002238.	2.0	0
21	Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	12
22	Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and Industry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 867-872.	0.4	3
23	Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 396-399.	0.9	19
24	Infectious disease consultation for candidaemia – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 165-166.	4.6	1
25	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	1.3	54
26	Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1336-1344.	4.6	72
27	Designing for Accelerated Translation (DART) of emerging innovations in health. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 53-58.	0.3	27
28	Presentation and Mortality of Cryptococcal Infection Varies by Predisposing Illness: A Retrospective Cohort Study. <i>American Journal of Medicine</i> , 2019, 132, 977-983.e1.	0.6	33
29	Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. <i>Mycoses</i> , 2019, 62, 554-561.	1.8	16
30	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e49-e52.	0.9	7
31	Mortality After Cryptococcal Infection in the Modern Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 81-87.	0.9	12
32	Brief Report: Aging Attenuates the Association Between Coronary Artery Calcification and Bone Loss Among HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 46-50.	0.9	0
33	Late Presentation and Missed Opportunities for HIV Diagnosis in Guatemala. <i>AIDS and Behavior</i> , 2019, 23, 920-928.	1.4	8
34	Creation and Assessment of a Clinical Predictive Calculator and Mortality Associated With <i>Candida krusei</i> Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx253.	0.4	11
35	Sex Venue-Based Network Analysis to Identify HIV Prevention Dissemination Targets for Men Who Have Sex with Men. <i>LGBT Health</i> , 2018, 5, 78-85.	1.8	5
36	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. <i>LGBT Health</i> , 2018, 5, 250-256.	1.8	23

#	ARTICLE	IF	CITATIONS
37	Comparative Epidemiology and Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ Transplant Associated Cryptococcosis: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 608-611.	2.9	81
38	Understanding mechanisms to promote successful aging in persons living with HIV. <i>International Journal of Infectious Diseases</i> , 2018, 66, 56-64.	1.5	30
39	376. Predictive Model for Fluconazole Resistance in Patient With Candida Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, S146-S146.	0.4	0
40	556. Factors Associated with Integrase Strand Transfer Inhibitor Use Between 2008 and 2015. <i>Open Forum Infectious Diseases</i> , 2018, 5, S206-S207.	0.4	0
41	394. Outcomes in Patients With Disseminated Noncentral Nervous System Cryptococcus. <i>Open Forum Infectious Diseases</i> , 2018, 5, S152-S152.	0.4	0
42	395. Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients From Florida. <i>Open Forum Infectious Diseases</i> , 2018, 5, S152-S152.	0.4	0
43	397. Long-Term Mortality of HIV Patients Following Cryptococcal Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, S153-S153.	0.4	0
44	EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy299.	0.4	23
45	1030. Risk Predictive Model for Candida Endocarditis in Patients with Candidemia: A 12-year Experience in a Single Tertiary Care Hospital. <i>Open Forum Infectious Diseases</i> , 2018, 5, S307-S307.	0.4	0
46	Cryptococcal meningitis in AIDS. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 152, 139-150.	1.0	23
47	HIV and its relationship to insulin resistance and lipid abnormalities. <i>Translational Research</i> , 2017, 183, 41-56.	2.2	37
48	Cryptococcosis Today: It Is Not All About HIV Infection. <i>Current Clinical Microbiology Reports</i> , 2017, 4, 88-95.	1.8	41
49	Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2017, 4, S75-S75.	0.4	0
50	Benefits of Direct-Acting Antivirals for Hepatitis C. <i>Annals of Internal Medicine</i> , 2017, 167, 812.	2.0	13
51	Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance. <i>Annals of Internal Medicine</i> , 2017, 167, 738.	2.0	4
52	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2017, 65, 1773-1775.	2.9	11
53	Comments on cochrane review on direct-acting antivirals for hepatitis C. <i>Hepatology</i> , 2017, 66, 1016-1019.	3.6	3
54	Conflicts of Interest Reported in an Abbreviated Time Frame. <i>JAMA Internal Medicine</i> , 2017, 177, 1059.	2.6	0

#	ARTICLE	IF	CITATIONS
55	Invasive Fungal Infections Secondary to Traumatic Injury. <i>International Journal of Infectious Diseases</i> , 2017, 62, 102-111.	1.5	49
56	Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 70-76.	1.1	14
57	Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV mono-infection. <i>Aids</i> , 2017, 31, 71-79.	1.0	20
58	Issues in the Aging HIV-Positive Patient. , 2017, , 927-930.e1.		0
59	Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a Large Retrospective Cohort of Patients After Solid Organ Transplantation. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx004.	0.4	53
60	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. <i>Antiviral Therapy</i> , 2017, 23, 379-382.	0.6	0
61	AIDS-Defining Illnesses at Initial Diagnosis of HIV in a Large Guatemalan Cohort. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx249.	0.4	10
62	Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx242.	0.4	30
63	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. <i>PLoS ONE</i> , 2017, 12, e0173057.	1.1	24
64	Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. <i>IDCases</i> , 2016, 6, 79-82.	0.4	7
65	Early Human Immunodeficiency Virus (HIV) Diagnosis in Guatemala: An Elusive Opportunity. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
66	Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw786.	2.9	44
67	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. <i>BMJ Open</i> , 2016, 6, e009586.	0.8	49
68	The Value of the Serum Aspergillus Galactomannan (GM) to Diagnose Invasive Aspergillosis (IA) and Invasive Fungal Infections (IFI) as Defined by European Organization of Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) in Recipients of Hematopoietic Stem Cell Transplants (HSCT).. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
69	End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv197.	0.4	45
70	Recommendations for Evaluation and Management of Bone Disease in HIV. <i>Clinical Infectious Diseases</i> , 2015, 60, 1242-1251.	2.9	150
71	Vitamin D and Calcium Abnormalities in the HIV-Infected Population. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 743-767.	1.2	8
72	Is There a Higher Risk of CNS Adverse Events for PI Monotherapy Versus Triple Therapy? A Review of Results From Randomized Clinical Trials. <i>HIV Clinical Trials</i> , 2014, 15, 79-86.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. <i>Journal of Hepatology</i> , 2014, 60, 508-514.	1.8	35
74	Antiretroviral therapy in primary HIV infection. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 227-229.	0.6	1
75	Beta-glucan for <i>Pneumocystis pneumonia</i> diagnosis in persons with AIDS. <i>Aids</i> , 2013, 27, 2967-2968.	1.0	1
76	Test performance of blood beta-glucan for <i>Pneumocystis jirovecii pneumonia</i> in patients with AIDS and respiratory symptoms. <i>Aids</i> , 2013, 27, 967-972.	1.0	35
77	Current advances in pharmacovigilance in the USA and Europe. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 292-298.	1.5	9
78	Documented Prevalence of HIV Type 1 Antiretroviral Transmitted Drug Resistance in Ireland from 2004 to 2008. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 276-281.	0.5	6
79	HIV-associated osteoporosis in Ireland: prevalence and risk factors. <i>Future Virology</i> , 2012, 7, 791-799.	0.9	0
80	Human Immunodeficiency Virus Type 1 in Ireland: Phylogenetic Evidence for Risk Group-Specific Subepidemics. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1073-1081.	0.5	3
81	Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: The BAN study. <i>Journal of Clinical Virology</i> , 2012, 54, 318-320.	1.6	19
82	<i>Candida</i> in HIV infection. , 2012, , 359-367.		1
83	Osteoporosis and Bone Health in HIV. <i>Current HIV/AIDS Reports</i> , 2012, 9, 218-222.	1.1	42
84	HIV Type 1 Alters Mesenchymal Stem Cell Differentiation Potential and Cell Phenotype <i>in vivo</i> . <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 187-199.	0.5	43
85	Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 501-515.	2.2	49
86	When to start antiretroviral therapy: asking the right question. <i>Future Virology</i> , 2011, 6, 401-403.	0.9	0
87	Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. <i>Aids</i> , 2011, 25, 1405-1414.	1.0	105
88	Blood (1->3)-D-Glucan as a Diagnostic Test for HIV-Related <i>Pneumocystis jirovecii</i> Pneumonia. <i>Clinical Infectious Diseases</i> , 2011, 53, 197-202.	2.9	104
89	GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. <i>The Open Virology Journal</i> , 2011, 5, 109-113.	1.8	8
90	Integrase inhibitors in the treatment of HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2485-2488.	1.3	49

#	ARTICLE	IF	CITATIONS
91	Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. <i>HIV Clinical Trials</i> , 2010, 11, 248-259.	2.0	17
92	A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2010, 11, 80-99.	2.0	13
93	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 291-322.	2.9	2,195
94	Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. <i>PLoS ONE</i> , 2010, 5, e11416.	1.1	135
95	Opportunistic infections. , 2010, , 964-974.		2
96	HIV: primary and secondary prophylaxis for opportunistic infections. <i>Clinical Evidence</i> , 2010, 2010, .	0.2	6
97	Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. <i>PLoS ONE</i> , 2009, 4, e5575.	1.1	460
98	Oral fungal infections. , 2009, , 501-508.		0
99	Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. <i>Aids</i> , 2009, 23, 1109-1118.	1.0	223
100	Management of late presentation in HIV: what the data tell us. <i>HIV Therapy</i> , 2009, 3, 423-426.	0.6	0
101	Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment. <i>Current HIV Research</i> , 2009, 7, 508-518.	0.2	2
102	Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 33.	0.8	36
103	Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 358, 2095-2106.	13.9	667
104	Editorial Commentary:Dosing Amphotericin B in Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2008, 47, 131-132.	2.9	7
105	Genetic analysis implicates resistin in HIV lipodystrophy. <i>Aids</i> , 2008, 22, 1561-1568.	1.0	42
106	Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 849-856.	1.0	29
107	Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk. <i>PLoS ONE</i> , 2008, 3, e2021.	1.1	56
108	Candida in HIV Infection. , 2008, , 365-373.		0

#	ARTICLE	IF	CITATIONS
109	Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E812-E819.	1.8	31
110	Association of Upper Trunk and Visceral Adipose Tissue Volume With Insulin Resistance in Control and HIV-Infected Subjects in the FRAM Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 283-290.	0.9	104
111	HIV Protease Inhibitors Selectively Induce Gene Expression Alterations Associated with Reduced Calcium Deposition in Primary Human Osteoblasts. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 243-250.	0.5	54
112	HIV Proteins Regulate Bone Marker Secretion and Transcription Factor Activity in Cultured Human Osteoblasts with Consequent Potential Implications for Osteoblast Function and Development. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1521-1530.	0.5	82
113	Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population. <i>Clinical Infectious Diseases</i> , 2007, 44, 726-734.	2.9	176
114	Cryptococcal infection. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 85, 159-167.	1.0	5
115	Osteopenia and osteoporosis in HIV: pathogenesis and treatment. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 318-323.	1.5	10
116	HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. <i>Antiviral Research</i> , 2007, 74, 72-76.	1.9	21
117	Clinical perspectives of emerging pathogens in bleeding disorders. <i>Lancet, The</i> , 2006, 367, 252-261.	6.3	60
118	Management of antiretroviral drug toxicity. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 430-436.	1.5	0
119	A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm <sup>3</sup> After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 140-148.	0.9	35
120	Nontuberculous Pyogenic Spinal Infection in Adults. <i>Spine</i> , 2006, 31, 2695-2700.	1.0	243
121	Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. <i>Aids</i> , 2006, 20, 2115-2116.	1.0	23
122	Whole-Body Proteolysis Rate Is Elevated in HIV-Associated Insulin Resistance. <i>Diabetes</i> , 2006, 55, 2849-2855.	0.3	34
123	APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4 + T-Cell Count. <i>Journal of Virology</i> , 2006, 80, 2069-2072.	1.5	66
124	Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 426-431.	0.9	136
125	Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. <i>Aids</i> , 2005, 19, 1439-1440.	1.0	8
126	Reducing plasma HIV RNA improves muscle amino acid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E278-E284.	1.8	31



#	ARTICLE	IF	CITATIONS
127	Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2005, 41, 1045-1048.	2.9	139
128	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. <i>Clinical Infectious Diseases</i> , 2005, 41, 1473-1480.	2.9	72
129	Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1326-1332.	2.9	70
130	Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 561-567.	1.5	32
131	Review: Hepatic Steatosis and HIV Infection. <i>AIDS Patient Care and STDs</i> , 2005, 19, 356-365.	1.1	44
132	Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 419-425.	2.9	64
133	Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits. <i>Clinical Infectious Diseases</i> , 2004, 38, S109-S113.	2.9	26
134	Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 180.	3.8	125
135	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. <i>Clinical Infectious Diseases</i> , 2004, 39, 98-106.	2.9	34
136	Osteoporosis in HIV-Infected Patients. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2004, 2, 167-174.	1.3	1
137	Evaluation of the Virological and Metabolic Effects of Switching Protease Inhibitor Combination Antiretroviral Therapy to Nevirapine-Based Therapy for the Treatment of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 589-594.	0.5	47
138	Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1. <i>Journal of Infectious Diseases</i> , 2004, 189, 286-291.	1.9	194
139	Has the Epidemiology of Nosocomial Candidemia Changed?. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 628-633.	1.0	71
140	Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. <i>Journal of Clinical Virology</i> , 2004, 31, 198-203.	1.6	6
141	Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 1011-1019.	0.9	288
142	The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. <i>Journal of Clinical Investigation</i> , 2004, 114, 206-213.	3.9	102
143	Gender-Specific Issues in Fungal Infections. , 2004, , 910-922.		1
144	Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3149-3154.	1.4	493

#	ARTICLE	IF	CITATIONS
145	A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients. <i>Clinical Infectious Diseases</i> , 2003, 37, 634-643.	2.9	746
146	Developing a Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Therapeutic Research Agenda for Resource-Limited Countries: A Consensus Statement. <i>Clinical Infectious Diseases</i> , 2003, 37, S4-S12.	2.9	9
147	Editorial Commentary: Centers for Disease Control and Prevention Revised Guidelines for Human Immunodeficiency Virus (HIV) Counseling, Testing, and Referral: Targeting HIV Specialists. <i>Clinical Infectious Diseases</i> , 2003, 37, 813-819.	2.9	13
148	Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2003, 36, 482-490.	2.9	286
149	Limitations of Current HIV Therapies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, S7-S12.	0.9	4
150	Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E899-E905.	1.8	23
151	Opportunities to improve clinical care in HIV disease: designing an effective antiretroviral drug regimen for your patient. Introduction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33 Suppl 1, S5-6.	0.9	0
152	A Controlled Phase II Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults. <i>Antiviral Therapy</i> , 2003, 8, 279-287.	0.6	63
153	Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+T Cell Decline in Human Immunodeficiency Virus-Infected Patients: Implications for Intermittent Therapeutic Strategies. <i>Journal of Infectious Diseases</i> , 2002, 186, 851-854.	1.9	50
154	Clinical: Overview. <i>Aids</i> , 2002, 16, S133-S134.	1.0	0
155	Sorting Through Confusing Messages: The Art of HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, S3-S9.	0.9	12
156	Long-term Exposure to Lifelong Therapies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, S28-S40.	0.9	102
157	Switching Effective Antiretroviral Therapy: A Review. <i>Clinical Infectious Diseases</i> , 2002, 35, 1219-1230.	2.9	95
158	Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Individuals for Whom Interferon- $\alpha$ and Lamivudine Therapy Have Failed. <i>Journal of Infectious Diseases</i> , 2002, 186, 1844-1847.	1.9	160
159	Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 257-275.	0.9	338
160	Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. <i>Annals of Internal Medicine</i> , 2002, 137, 105.	2.0	304
161	Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. <i>Journal of Applied Physiology</i> , 2001, 90, 133-138.	1.2	111
162	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. <i>Aids</i> , 2001, 15, 591-599.	1.0	18

#	ARTICLE	IF	CITATIONS
163	OVERVIEW. <i>Aids</i> , 2001, 15, S159-S160.	1.0	3
164	Sex Differences in Nevirapine Rash. <i>Clinical Infectious Diseases</i> , 2001, 32, 124-129.	2.9	204
165	A prospective study of discontinuing primary and secondary <i>Pneumocystis carinii</i> pneumonia prophylaxis after CD4 cell count increase to > 200 Å– 106/l. <i>Aids</i> , 2001, 15, 1509-1515.	1.0	25
166	Treatment of acute cryptococcal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1259-1268.	0.9	9
167	Elevated Lactate Levels in Hospitalized Persons with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 195-201.	0.5	16
168	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. <i>Aids</i> , 2000, 14, 979-985.	1.0	78
169	Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. <i>Aids</i> , 2000, 14, F63-F67.	1.0	455
170	Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. <i>Antiviral Research</i> , 2000, 45, 47-58.	1.9	23
171	Cryptococcal meningitis in HIV-infected patients. <i>Current Infectious Disease Reports</i> , 2000, 2, 352-357.	1.3	30
172	Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. <i>Aids</i> , 2000, 14, 845-852.	1.0	30
173	Nelfinavir mesylate. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 1429-1440.	0.9	24
174	In Vivo Virulence of <i>Candida albicans</i> isolates Causing Mucosal Infections in People Infected with the Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2000, 182, 955-959.	1.9	34
175	Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2000, 30, 749-756.	2.9	93
176	PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS. <i>Infectious Disease Clinics of North America</i> , 2000, 14, 929-944.	1.9	5
177	Response to “Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy” by Drs Weil and Lenhard. <i>Aids</i> , 2000, 14, 2417.	1.0	16
178	Insulin Resistance in HIV Protease Inhibitor-Associated Diabetes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 21, 209.	0.9	129
179	Predictors of optimal virological response to potent antiretroviral therapy. <i>Aids</i> , 1999, 13, 1873-1880.	1.0	167
180	Clinical Perspective Oropharyngeal Candidiasis in Patients with HIV: Suggested Guidelines for Therapy. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1619-1623.	0.5	38

#	ARTICLE	IF	CITATIONS
181	Diagnosis and Treatment of Oropharyngeal Candidiasis in Patients Infected with HIV: A Critical Reassessment. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1405-1412.	0.5	64
182	Immune reconstitution and the consequences for opportunistic infection treatment and prevention. <i>Current Infectious Disease Reports</i> , 1999, 1, 99-104.	1.3	4
183	The interaction of opportunistic infections and HIV replication. <i>Aids</i> , 1999, 13, 1603-1006.	1.0	11
184	Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. <i>Aids</i> , 1999, 13, F23-F28.	1.0	134
185	Pulmonary Cryptococcosis in Patients Without HIV Infection. <i>Chest</i> , 1999, 115, 734-740.	0.4	174
186	TREATMENT OF INFECTION DUE TO MYCOBACTERIUM AVIUM COMPLEX. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 468-469.	1.1	5
187	A Randomized, Double-blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1998, 177, 48-56.	1.9	130
188	Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1998, 26, 556-565.	2.9	71
189	Recovery of the Immune System With Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 72.	3.8	196
190	Effect of Opportunistic Illness on Risk of Death in HIV Disease. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1500.	3.8	1
191	Phase I Study of Atevidine Mesylate (U-87201E) Monotherapy in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 135-144.	0.3	10
192	A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated <i>Mycobacterium avium</i> infection in HIV-infected individuals. <i>Aids</i> , 1998, 12, 2439-2446.	1.0	19
193	Increased plasma Gln and Leu Raand inappropriately low muscle protein synthesis rate in AIDS wasting. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E577-E583.	1.8	40
194	Invasive Fungal Infections: Cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1997, 18, 249-257.	0.8	8
195	Molecular Epidemiology of Mucosal Candidiasis in HIV-Positive Women. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 485-491.	0.5	15
196	Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1997, 337, 15-21.	13.9	745
197	<a href="#">Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency Syndrome</a> This study has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Contract Numbers: NO1-AI-15082 and NO1-AI-65296; the AIDS Clinical Trials Group and the Mycoses Study Group (Contract Numbers) Tj ETQq1 1 0.784314 rgBT /Overbo	0.6	149
198	<a href="#">Institutes of Health Genera. American Journal of Medicine</a> , 1997, 103, 223-232. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 303-305.	1.5	64

#	ARTICLE	IF	CITATIONS
199	Cytomegalovirus Retinitis Treatment. JAMA - Journal of the American Medical Association, 1997, 278, 1287.	3.8	0
200	Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management, 1997, 14, 7-14.	0.6	184
201	Itraconazole Maintenance Treatment for Histoplasmosis in AIDS: A Prospective, Multicenter Trial. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 100-107.	0.3	56
202	Prophylaxis for HIV-Related Infections: A Work in Progress. Annals of Internal Medicine, 1996, 124, 342.	2.0	4
203	Opportunistic infections. Current Opinion in Infectious Diseases, 1996, 9, 23-27.	1.3	0
204	Cryptococcosis. Advances in Pharmacology, 1996, 37, 215-251.	1.2	14
205	Sequence Heterogeneity of Nef Transcripts in HIV-1-Infected Subjects at Different Stages of Disease. Virology, 1996, 223, 245-250.	1.1	15
206	Recent Advances in the Management of Cryptococcal Meningitis in Patients with AIDS. Clinical Infectious Diseases, 1996, 22, S119-S123.	2.9	53
207	Rifabutin Induced Vitritis in AIDS Patients. Ocular Immunology and Inflammation, 1996, 4, 219-224.	1.0	3
208	A Phase II Study of Recombinant Human Interferon- $\alpha$ 2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma. Journal of Acquired Immune Deficiency Syndromes, 1996, 11, 379-384.	0.3	39
209	Patterns of Opportunistic Infections in Patients with HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 38-45.	0.3	48
210	Authors' Reply: Campylobacter spp. Bacteremia in AIDS Patients. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 94.	0.3	0
211	RISKS OF HIV INFECTION IN THE HEALTH CARE SETTING. Annual Review of Medicine, 1995, 46, 203-211.	5.0	13
212	Risk Factors for Dideoxynucleoside-Induced Toxic Neuropathy in Patients with the Human Immunodeficiency Virus Infection. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 169-174.	0.3	46
213	USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: An Overview*. Clinical Infectious Diseases, 1995, 21, S12-S31.	2.9	84
214	A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 693-699.	13.9	341
215	Prospects for Preventing Cryptococcosis in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1995, 21, S103-S107.	2.9	64
216	A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection. New England Journal of Medicine, 1995, 333, 1534-1540.	13.9	482

#	ARTICLE	IF	CITATIONS
217	Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. <i>American Journal of Medicine</i> , 1995, 98, 336-342.	0.6	237
218	A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1995, 332, 700-705.	13.9	333
219	Resistant Candidiasis. <i>AIDS Patient Care and STDs</i> , 1995, 9, 32-36.	0.2	1
220	Measurement of Cryptococcal Antigen in Serum and Cerebrospinal Fluid: Value in the Management of AIDS-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 1994, 18, 789-792.	2.9	171
221	Serious <i>Pseudomonas aeruginosa</i> Infections in Patients Infected with Human Immunodeficiency Virus: A Case-Control Study. <i>Clinical Infectious Diseases</i> , 1994, 19, 417-422.	2.9	70
222	Resistant Candidiasis. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 925-929.	0.5	59
223	Resistance to amphotericin B associated with defective sterol 8 $\alpha$ -isomerase in a <i>Cryptococcus neoformans</i> strain from an AIDS patient. <i>FEMS Microbiology Letters</i> , 1994, 122, 39-42.	0.7	120
224	Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. <i>American Journal of Medicine</i> , 1993, 95, 273-278.	0.6	47
225	Symptomatic Cytomegalovirus Infection in Renal Transplant Recipients Given Either Minnesota Antilymphoblast Globulin (MALG) or OKT3 for Rejection Prophylaxis. <i>American Journal of Kidney Diseases</i> , 1993, 21, 196-201.	2.1	23
226	Molecular Epidemiology of Recurrent Oral Candidiasis in Human Immunodeficiency Virus-Positive Patients: Evidence for Two Patterns of Recurrence. <i>Journal of Infectious Diseases</i> , 1993, 168, 463-466.	1.9	87
227	Alterations in Spliced and Unspliced HIV-1-Specific RNA Detection in Peripheral Blood Mononuclear Cells of Individuals with Varying CD4-Positive Lymphocyte Counts. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 1257-1263.	0.5	18
228	A Controlled Trial of Trimethoprim-Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1992, 327, 1842-1848.	13.9	365
229	Therapy for Cryptococcal Meningitis in Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1992, 14, S54-S59.	2.9	90
230	Failure of Prophylactic Ganciclovir to Prevent Cytomegalovirus Disease in Recipients of Lung Transplants. <i>Journal of Infectious Diseases</i> , 1992, 165, 548-552.	1.9	83
231	Molecular typing of <i>Candida albicans</i> isolated from oral lesions of HIV-infected individuals. <i>Aids</i> , 1992, 6, 81-84.	1.0	71
232	A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1992, 326, 845-851.	13.9	1,175
233	Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 1992, 326, 83-89.	13.9	643
234	A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1992, 326, 793-798.	13.9	362

#	ARTICLE	IF	CITATIONS
235	Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine, 1988, 84, 826-832.	0.6	238
236	Renal glomerulopathies associated with Hodgkin's disease. Cancer, 1985, 56, 874-875.	2.0	17
237	Cryptococcus. , 0, , 1205-1210.		0
238	Cryptococcus. , 0, , 1128-1133.		0